Marlin’s new risk limits face a test after a 6.3% portfolio decline

Marlin’s FY2026 loss exposes a 36.8-point performance gap

Marlin Global Limited (NZX:MLN) is putting tighter limits around its portfolio after an exceptionally weak year left it with a NZ$17.3 million net loss and a 36.8 percentage-point gap to its benchmark. The portfolio’s gross return fell 6.3% for the year ended 30 June 2026, while the S&P Large Mid Cap/S&P Small Cap Index, hedged 50% to NZD, rose 30.5%.

The damage was also visible in shareholder returns. Marlin’s adjusted net asset value return was negative 8.5%, total shareholder return was negative 7.6%, and the share price fell to NZ$0.77 from NZ$0.91. Dividends provided 7.35 cents per share, equivalent to an 8.1% dividend return based on the average share price, but did not offset the capital decline. The company’s three- and five-year portfolio returns also remained below the benchmark.

The result had already been identified in FY26 loss and benchmark gap, where Marlin said its Fisher Funds-managed portfolio was responding with broader sector coverage, faster portfolio turnover and a larger research team. At the annual meeting, Chair Fiona Oliver described the performance as disappointing in both absolute and relative terms.

New guardrails limit concentration and tracking risk

From 6 November, the management framework includes an ex-ante tracking error ceiling of 12%, with an expectation of 9% over a full market cycle. Marlin must hold at least 25 stocks, while active positions are capped at 6% at cost and absolute positions at 10%, based on market size.

Sector exposure will also be constrained to no more than 10% above the relevant GICS index. The board, rather than the manager, will decide the currency hedging strategy, which has yet to be determined. Expanded reporting is intended to allow the board to assess the portfolio against the new parameters. The measures arrive as Marlin prepares to negotiate a new management agreement before the current five-year term expires towards the end of 2027.

Portfolio expands as Marlin reduces healthcare exposure

The investment team says it reviewed every holding, its past contribution to returns and the portfolio’s risk management. The resulting changes took Marlin from 26 holdings to 36, with eight exits and 18 new positions. Healthcare exposure was reduced, while industrials and financials increased, alongside greater geographic and sector diversification.

Research capacity has also grown from four analysts to seven, with an analyst assigned to each major sector. That is a meaningful change in process, but it does not yet settle whether the new structure can consistently close the performance gap against a benchmark that has benefited heavily from AI-linked market leadership.

Early FY2027 rebound narrows the immediate concern

Marlin began the new financial year on firmer footing. For the three months to 30 September, it reported a NZ$6.1m net profit and a 4.0% gross performance return, compared with a 1.1% decline in the benchmark. The presentation attributed the improvement to several previous laggards leading portfolio returns, although the period is too short to establish whether the shift is durable.

Capital management remains part of the board’s response. Marlin bought back 1.5 million shares in the September quarter and another 1.2 million in October, after no buybacks in FY2026 because the share price did not trade at the policy trigger of more than a 6% discount to fair-value adjusted NAV. At 30 September, however, the share price was NZ$0.66, an 18% discount to NAV.

The key test now is not simply whether Marlin can produce a positive quarter. It is whether the new limits can reduce the cost of concentrated bets without preventing the manager from participating when markets again reward a narrow group of high-growth stocks.